Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Siegenthaler, M; Huynh-Do, Uyen; Krayenbuehl, P; Pollock, E; Widmer, U; Debaix, H; Olinger, E; Frank, M; Namdar, M; Ruschitzka, F; Nowak, Albina (2017). Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. International Journal of Cardiology, 249:261-267.

Kovacevic-Preradovic, T; Zuber, M; Attenhofer Jost, C H; Widmer, U; Seifert, Burkhardt; Schulthess, G; Fischer, A; Jenni, R (2008). Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. European Journal of Echocardigraphy, 9(6):729-735.

Palla, A; Hegemann, S; Widmer, U; Straumann, D (2007). Vestibular and auditory deficits in fabry disease and their response to enzyme replacement therapy. Journal of Neurology, 254(10):1433-1442.

Hajioff, D; Hegemann, S; Beck, M; Conti, G; Sunder-Plassmann, G; Widmer, U; Mehta, A; Keilmann, A (2006). Agalsidase alpha and hearing in fabry disease: data from the fabry outcome surve. European Journal of Clinical Investigation, 36(9):663-667.

Hegemann, S; Hajioff, D; Conti, G; Beck, M; Sunder-Plassmann, G; Widmer, U; Mehta, A; Keilmann, A (2006). Hearing loss in Fabry disease: data from the Fabry Outcome Survey. European Journal of Clinical Investigation, 36(9):654-662.

Hoigné, P; Attenhofer Jost, C H; Duru, F; Oechslin, E N; Seifert, Burkhardt; Widmer, U; Frischknecht, B; Jenni, R (2006). Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. International Journal of Cardiology, 111(3):413-422.

This list was generated on Tue Nov 21 00:50:51 2017 CET.